摘要
目的观察微粒化非诺贝特与阿托伐他汀对高脂血症合并高尿酸血症的治疗效果。方法55例高血脂症合并高尿酸血症患者随机分为两组。治疗组30例给予微粒化非诺贝特200mg／d；对照组25例给予阿托伐他汀10mg／d。两组患者均给治疗8周。比较两组临床疗效、血脂和血尿酸水平及不良反应。结果两组治疗后与治疗前比较，甘油三酯（TG）、总胆固醇（TC）差异均有统计学意义。治疗后治疗组与对照组TG差异有统计学意义。治疗组降低血尿酸效果好于对照组。两组均无严重不良反应。结论非诺贝特与阿托伐他汀均可用于高血酸症及高脂血症治疗，短时间内使血脂达标，减少脑血管病的危险因素。
Objective To explore the effect of fenofibrate and atorvastatin on hyperlipoidemia and hyperuricemia. Methods 55 cases were randomly divided into 2 groups. 30 cases in the treatment group were give Fenofibrate （200mg/d） and 25 cases in control group were given atorvastatin（10mg/d）. And two groups given 8 days for all patients. The therapeutic effect, blood-fat and blood uric acid level, and complication in two groups were compared. Re- suits There were conspicuous effect of fenofibrate and atorvastatin on hyperlipoidemia and hyperuricemia. The index of TG, TC had significant differences between the two groups. The index of acidum uricum was higher in control group. The complication had no significant differences between two groups. Conclusion Both fenofibrate and atorvastain were effective drug for hyperuricemia and hyperlipoidemia, and could reduce TC, TG, HDLC and LDLC in the short time, and could decrease the risk factor of cerebrovascular disease.
出处
《中国基层医药》
CAS
2011年第17期2311-2312,共2页
Chinese Journal of Primary Medicine and Pharmacy
基金
基金项目：黑龙江省教育厅科学技术研究项目（11531159）
